Impact of physician counseling and perception of teratogenic risks: A survey of 96 nonpregnant women with anxiety

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 2, 2011, Pages

  Behringer, Tiffany ^a   Rollman, Bruce L ^a   Herbeck Belnap, Bea ^a   Houck, Patricia R ^b   Mazumdar, Sati ^c   Schwarz, Eleanor Bimla ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Department of Psychiatry ^*  (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; ATTITUDE TO HEALTH; BIRTH DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PANIC; PATIENT COUNSELING; PATIENT DECISION MAKING; PHYSICIAN ATTITUDE; PREGNANCY OUTCOME; PRIMARY MEDICAL CARE; PSYCHOLOGICAL RATING SCALE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; TERATOGENESIS;

EID: 79957716410     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.10m01028     Document Type: Article

References (34)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. PubMed doi:10.1001/archpsyc.62.6.593
2. Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62(10):863-870. PubMed doi:10.1007/s00228-006-0177-0
3. Doering PL, Stewart RB. The extent and character of drug consumption during pregnancy. JAMA. 1978;239(9):843-846. PubMed doi:10.1001/jama.239.9.843
4. Marchetti F, Romero M, Bonati M, et al; Collaborative Group on Drug Use in Pregnancy (CGDUP). Use of psychotropic drugs during pregnancy: A report of the International Co-Operative Drug Use in Pregnancy (DUP) study. Eur J Clin Pharmacol. 1993;45(6):495-501. PubMed doi:10.1007/BF00315304
5. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339(Sept 23):b3569. PubMed doi:10.1136/bmj.b3569
6. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88(2):94-100. PubMed
7. GlaxoSmithKline. Use of Paxil CR tablets or Paxil tablets during pregnancy. http://www.gsk.com/media/paroxetine/mi_letter_paroxetine_pregnancy.pdf. Accessed January 18, 2011.
8. Aarskog D. Letter: association between maternal intake of diazepam and oral clefts. Lancet. 1975;2(7941):921. PubMed doi:10.1016/S0140-6736(75)92153-4
9. Kellogg CK. Benzodiazepines: influence on the developing brain. Prog Brain Res. 1988;73:207-228. PubMed doi:10.1016/S0079-6123(08)60506-3
10. Saxén I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol. 1975;4(1):37-44. PubMed doi:10.1093/ije/4.1.37
11. Einarson A. The safety of psychotropic drug use during pregnancy: a review. MedGenMed. 2005;7(4):3. PubMed
12. Alwan S, Reefhuis J, Rasmussen SA, et al; National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684-2692. PubMed doi:10.1056/NEJMoa066584
13. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008;165(6):749-752. PubMed doi:10.1176/appi.ajp.2007.07060879
14. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106(6):1289-1296. PubMed doi:10.1097/01.AOG.0000187302.61812.53
15. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269(17):2246-2248. PubMed doi:10.1001/jama.269.17.2246
16. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015. PubMed doi:10.1056/NEJM199610033351402
17. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055-2061. PubMed doi:10.1176/appi.ajp.159.12.2055
18. Ornoy A, Arnon J, Shechtman S, et al. Is benzodiazepine use during pregnancy really teratogenic? Reprod Toxicol. 1998;12(5):511-515. PubMed doi:10.1016/S0890-6238(98)00035-5
19. Calderon-Margalit R, Qiu C, Ornoy A, et al. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol. 2009;201(6):579, e1-e8. PubMed doi:10.1016/j.ajog.2009.06.061
20. Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210. PubMed doi:10.1002/pds.1457
21. Eros E, Czeizel AE, Rockenbauer M, et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002;101(2):147-154. PubMed doi:10.1016/S0301-2115(01)00545-0
22. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8(6):461-475. PubMed doi:10.1016/0890-6238(94)90029-9
23. Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317(7162):839-843. PubMed
24. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol. 2009;29(6):555-560. PubMed doi:10.1097/JCP.0b013e3181bf344c
25. Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet. 2008;277(1):1-13. PubMed doi:10.1007/s00404-007-0433-2
26. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry. 1998;59(suppl 2):18-28. PubMed
27. Beijers R, Jansen J, Riksen-Walraven M, et al. Maternal prenatal anxiety and stress predict infant illnesses and health complaints. Pediatrics. 2010;126(2):e401-e409. PubMed doi:10.1542/peds.2009-3226
28. Bhagwanani SG, Seagraves K, Dierker LJ, et al. Relationship between prenatal anxiety and perinatal outcome in nulliparous women: a prospective study. J Natl Med Assoc. 1997;89(2):93-98. PubMed
29. Van den Bergh BR, Marcoen A. High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems, and anxiety in 8- and 9-year-olds. Child Dev. 2004;75(4):1085-1097. PubMed doi:10.1111/j.1467-8624.2004.00727.x
30. Santucci AK, Gold MA, Akers AY, et al. Women's perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2010;88(1):64-69. PubMed
31. Schwarz EB, Santucci A, Borrero S, et al. Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol. 2009;85(10):858-863. PubMed doi:10.1002/bdra.20599
32. Rollman BL, Fischer GS, Zhu F, et al. Comparison of electronic physician prompts versus waitroom case-finding on clinical trial enrollment. J Gen Intern Med. 2008;23(4):447-450. PubMed doi:10.1007/s11606-007-0449-0
33. Centers for Disease Control. Updated overall prevalence of major birth defects: Atlanta, Georgia 1978-2005. MMWR. 2008;57(01):1-5. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm. Accessed January 18, 2011.
34. Russo CA, Elixhauser A. Hospitalizations for birth defects, 2004. HCUP Statistical Brief #24. Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb24.pdf. Accessed January 18, 2011.